8-K: Recursion Pharma Reports Q2 Results, Genentech Options Target

Recursion Pharmaceuticals announced strong pipeline execution and platform advancements in Q2 2026, highlighted by Genentech exercising an option for a neuroscience target and positive clinical updates for REC-4881 and REC-7735.

Summary

• Recursion Pharmaceuticals reported Q2 2026 results, showcasing progress in its AI-native platform and drug development pipeline.
• Genentech advanced the first neuroscience target from the collaboration into an early discovery program, validating Recursion's platform for novel target identification.
• Clinical updates include expected Phase 2 data for REC-4881 in Familial Adenomatous Polyposis (FAP) in November 2026 and IND clearance for REC-7735, with Phase 1/2 trial initiation in 2H26.
• The company reduced its 2026 cash operating expense guidance to under $375 million from under $390 million.
• Total revenue for Q2 2026 was $7.7 million, a decrease from $19.2 million in Q2 2025, primarily due to the completion of project phases in the prior period with Roche and Genentech.
• Research and development expenses decreased to $89.6 million from $128.6 million year-over-year, while general and administrative expenses also decreased to $41.5 million from $46.7 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, with significant progress in pipeline execution, platform advancement, and strategic collaborations, offset by a decrease in current quarter revenue.

Positives

• Genentech exercised its first Validated Target Option under the neuroscience collaboration, advancing a novel target into an early discovery program.
• Recursion's AI-native platform demonstrated its ability to discover and validate novel therapeutic targets in challenging areas like neuroscience.
• REC-4881 (MEK1/2 inhibitor) is progressing with additional Phase 2 data expected in November 2026, and discussions with the FDA are underway to define the registrational path.
• REC-7735 (PI3K H1047R inhibitor) has received IND clearance, with a Phase 1/2 trial planned for the second half of 2026.
• The company reduced its full-year 2026 cash operating expense guidance by $15 million to under $375 million.
• Cash, cash equivalents, and restricted cash were $556.8 million as of June 30, 2026, with an expected cash runway into early 2028.
• Two key leadership positions were strengthened with the appointments of Hoifung Poon, Ph.D. as Chief AI Officer and Donovan Chin, Ph.D. as Senior Vice President, Drug Design.

Negatives

• Total revenue for the second quarter of 2026 was $7.7 million, a significant decrease from $19.2 million in the second quarter of 2025.
• Net loss for Q2 2026 was $131.0 million, compared to $171.9 million in Q2 2025, indicating continued operational losses.
• Net cash used in operating activities increased to $105.9 million for Q2 2026, from $76.4 million in Q2 2025.

Risks

• Forward-looking statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
• Challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high.
• Reliance on third parties, including collaborators, contract research organizations, and manufacturers.
• Ability to obtain regulatory approval of, and ultimately commercialize, drug candidates.
• Competition from other therapies and platforms.
• Inflation and other macroeconomic issues.

Future Outlook

The company expects its cash runway to extend into early 2028 based on current operating plans and no additional financing. Guidance for 2026 cash operating expenses has been reduced to under $375 million. Upcoming milestones include additional Phase 2 data for REC-4881 and Phase 1 data for REC-1245 in 2H26, and the initiation of the REC-7735 Phase 1/2 trial in 2H26.

Management Comments

• "The advancement of the first unexplored neuroscience target from our collaboration with Roche and Genentech into an early discovery program is an important proof point. Finding new targets in neuroscience has historically been challenging, and this milestone highlights our ability to uncover novel biology in areas where conventional approaches have struggled."
• "We believe that combining disease-relevant data at scale, foundation models, an end-to-end learning system, and deep scientific collaboration can uncover new biology in ways that were not previously possible."

Industry Context

StockSavvy.ai notes that Recursion's progress aligns with the broader trend of TechBio companies leveraging AI and large datasets to accelerate drug discovery. The advancement of a neuroscience target by Genentech validates the potential of AI-driven target identification in a historically challenging therapeutic area. The company's focus on platform development and pipeline execution is a common strategy in the competitive biopharmaceutical landscape.

Comparison to Industry Standards

• The company's AI-native platform aims to reduce drug discovery timelines and costs compared to traditional methods, with stated improvements in compound synthesis and candidate identification speed.
• Recursion's approach to building multimodal maps of biology and leveraging agentic AI for target discovery, drug design, and clinical strategy is a novel methodology aiming to outperform industry baselines.
• The company's cash operating expense guidance reduction and extended cash runway into early 2028 suggest disciplined financial management, which is crucial for biotech companies in the current economic climate.
• The advancement of multiple internal pipeline candidates (REC-4881, REC-7735, REC-1245) into later stages of development, alongside significant partnership milestones, indicates a robust R&D engine compared to many peers.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact from pipeline progress, platform validation, and cost reduction efforts, offset by revenue decline and continued net loss.
• Employees: Potential impact from headcount reductions mentioned in G&A expense decrease, but also positive impact from new leadership in AI and Drug Design.
• Partners (Roche, Genentech, Sanofi): Continued collaboration and milestone achievements reinforce the value of these partnerships.
• Patients: Potential long-term benefit from advancing novel therapies like REC-4881 for FAP and REC-7735 for oncology.

Next Steps

• Advance the Genentech-optioned neuroscience target through small molecule design, hit generation, and validation using Recursion's AI-native chemistry platform.
• Present additional Phase 2 safety and efficacy data for REC-4881 at the CGA-IGC Annual Meeting in November 2026.
• Initiate the Phase 1/2 ZINNIA clinical study for REC-7735 in patients with select PIK3CA H1047R-mutant solid tumors in the second half of 2026.
• Continue enrollment in the TUPELO trial for REC-4881.
• Engage with the FDA in 2H26 to define the registrational path for REC-4881.
• Provide additional Phase 1 dose escalation data for REC-1245 in 2H26.
• Advance Sanofi programs towards development candidate and late-stage discovery milestones over the next 6-12 months.

Key Dates

Recommendation

Recursion Pharmaceuticals is demonstrating strong execution in its AI platform and pipeline development, with key milestones achieved and upcoming catalysts. However, the significant decrease in revenue and continued net losses, alongside the inherent risks in drug development, warrant a cautious approach. The company's cash runway is positive, and cost-saving measures are encouraging, but the path to profitability and market-approved therapies still involves substantial risk and time. Therefore, a 'hold' recommendation is appropriate, pending further clinical data and revenue growth.

Keywords

Recursion Pharmaceuticals, TechBio, AI drug discovery, REC-4881, REC-7735, Familial Adenomatous Polyposis, PI3K inhibitor, Neuroscience collaboration